Clinical TrialMay 22, 2026, 04:13 PM
Fennec Announces New PEDMARK Research at ASCO Meeting
AI Summary
Fennec Pharmaceuticals announced that new research evaluating PEDMARK (sodium thiosulfate injection) will be shared at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Four independently led studies expand the understanding of PEDMARK 's clinical utility in Adolescent and Young Adult (AYA) and adult populations, building on its established safety and efficacy. The research highlights the potential for PEDMARK to address cisplatin-induced ototoxicity more broadly and integrate into patient care without compromising antitumor activity.
Key Highlights
- Four independently led studies on PEDMARK will be presented at the 2026 ASCO Annual Meeting.
- Japanese Children Cancer Group STS-J01 study showed 16-24% hearing loss with PEDMARK vs. 56-63% historically.
- Retrospective case series of 9 AYA/adult patients demonstrated PEDMARK feasibility and no interference with cisplatin activity.
- Multi-institutional review of 15 adults with head and neck cancers showed PEDMARK preserved clinically significant hearing.
- A randomized Phase 1 trial for metastatic germ cell tumor patients opened to accrual in January 2026.
- PEDMARK is approved for pediatric patients 1 month and older with localized, non-metastatic solid tumors.
Price Impact
More from FENC